Supplementary Table 1: Patient and disease characteristics

(A) All patients

		All patients (n=42)
Age, yrs, median (IQR)		67 (64–70)
PSA, ng/ml, median (IQR)		10.2 (5.7–22.5)
Pathologic classification, n		
	T2a	1
	T2b	0
	T2c	18
	T3a	12
	T3b	11
	T4	0
Pathologic Gleason score, n		
	3+3	5
	3+4	10
	4+3	14
	4+4	2
	3+5	1
	5+3	1
	4+5	7
	5+4	2
Number lymph nodes removed, median (IQR)		35 26–42)

(B) Patients who received sextant ICG injections

		All patients (n=12)
Age, yrs, median (IQR)		67.5 (60.8–71.5)
PSA, ng/ml, median (IQR)		11.2 (5.2–46.7)
Pathologic classification, n		
	T2a	0
	T2b	0
	T2c	4 (33)
	T3a	5 (42)
	T3b	3 (25)
	T4	0
Pathologic Gleason score, n		
	3+3	2 (17)
	3+4	2 (17)
	4+3	4 (33)
	4+4	0
	3+5	0
	5+3	0
	4+5	4 (33)
	5+4	0
Number lymph nodes removed, median (IQR)		31 (24–42)

Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.

source: https://doi.org/10.7892/boris.80964 | downloaded: 12.10.2024